Wellington Management Group LLP Acquires 423,543 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

Wellington Management Group LLP grew its holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 142.1% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 721,581 shares of the company's stock after purchasing an additional 423,543 shares during the period. Wellington Management Group LLP owned approximately 0.72% of Day One Biopharmaceuticals worth $10,052,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Mirae Asset Global Investments Co. Ltd. boosted its stake in Day One Biopharmaceuticals by 38.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,611 shares of the company's stock valued at $51,000 after buying an additional 1,002 shares in the last quarter. Quest Partners LLC boosted its stake in shares of Day One Biopharmaceuticals by 9,238.6% in the 3rd quarter. Quest Partners LLC now owns 7,751 shares of the company's stock valued at $108,000 after purchasing an additional 7,668 shares in the last quarter. SG Americas Securities LLC bought a new stake in shares of Day One Biopharmaceuticals during the 2nd quarter valued at approximately $113,000. Point72 DIFC Ltd bought a new stake in shares of Day One Biopharmaceuticals during the 2nd quarter valued at approximately $124,000. Finally, Hsbc Holdings PLC acquired a new position in Day One Biopharmaceuticals during the 2nd quarter worth approximately $163,000. Institutional investors own 87.95% of the company's stock.

Analyst Ratings Changes

A number of analysts have weighed in on the stock. Needham & Company LLC restated a "buy" rating and issued a $33.00 target price on shares of Day One Biopharmaceuticals in a research report on Thursday, October 31st. TD Cowen upgraded Day One Biopharmaceuticals to a "strong-buy" rating in a research note on Monday, November 4th. Finally, HC Wainwright restated a "buy" rating and set a $40.00 price objective on shares of Day One Biopharmaceuticals in a research report on Thursday, October 31st. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Day One Biopharmaceuticals presently has an average rating of "Buy" and a consensus target price of $35.71.

Insiders Place Their Bets

In related news, insider Samuel C. Blackman sold 10,000 shares of the company's stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $16.10, for a total transaction of $161,000.00. Following the sale, the insider now owns 1,057,535 shares in the company, valued at $17,026,313.50. This represents a 0.94 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In the last ninety days, insiders sold 51,745 shares of company stock worth $748,567. Company insiders own 8.40% of the company's stock.

Day One Biopharmaceuticals Stock Performance

Shares of NASDAQ:DAWN traded down $0.13 during mid-day trading on Monday, reaching $12.62. 726,585 shares of the company's stock were exchanged, compared to its average volume of 957,916. The firm has a market capitalization of $1.27 billion, a price-to-earnings ratio of -12.25 and a beta of -1.51. Day One Biopharmaceuticals, Inc. has a twelve month low of $11.94 and a twelve month high of $18.07. The business's fifty day moving average price is $14.17 and its 200-day moving average price is $14.04.

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last released its earnings results on Wednesday, October 30th. The company reported $0.38 earnings per share for the quarter, beating analysts' consensus estimates of ($0.20) by $0.58. The firm had revenue of $93.76 million for the quarter, compared to analyst estimates of $15.05 million. During the same period in the prior year, the company posted ($0.54) EPS. Analysts predict that Day One Biopharmaceuticals, Inc. will post -0.88 EPS for the current fiscal year.

Day One Biopharmaceuticals Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.